JP2011190259A5 - - Google Patents

Download PDF

Info

Publication number
JP2011190259A5
JP2011190259A5 JP2011052316A JP2011052316A JP2011190259A5 JP 2011190259 A5 JP2011190259 A5 JP 2011190259A5 JP 2011052316 A JP2011052316 A JP 2011052316A JP 2011052316 A JP2011052316 A JP 2011052316A JP 2011190259 A5 JP2011190259 A5 JP 2011190259A5
Authority
JP
Japan
Prior art keywords
composition
pharmaceutically acceptable
acceptable excipient
disintegrant
methylnaltrexone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011052316A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011190259A (ja
JP6143409B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011190259A publication Critical patent/JP2011190259A/ja
Publication of JP2011190259A5 publication Critical patent/JP2011190259A5/ja
Application granted granted Critical
Publication of JP6143409B2 publication Critical patent/JP6143409B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011052316A 2010-03-11 2011-03-10 メチルナルトレキソンの経口製剤および親油性塩 Active JP6143409B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31301810P 2010-03-11 2010-03-11
US61/313,018 2010-03-11

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015178184A Division JP2016029054A (ja) 2010-03-11 2015-09-10 メチルナルトレキソンの経口製剤および親油性塩

Publications (3)

Publication Number Publication Date
JP2011190259A JP2011190259A (ja) 2011-09-29
JP2011190259A5 true JP2011190259A5 (enExample) 2013-12-12
JP6143409B2 JP6143409B2 (ja) 2017-06-07

Family

ID=44148539

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2011052316A Active JP6143409B2 (ja) 2010-03-11 2011-03-10 メチルナルトレキソンの経口製剤および親油性塩
JP2015178184A Pending JP2016029054A (ja) 2010-03-11 2015-09-10 メチルナルトレキソンの経口製剤および親油性塩
JP2017152275A Active JP6429955B2 (ja) 2010-03-11 2017-08-07 メチルナルトレキソンの経口製剤および親油性塩
JP2018203748A Active JP6647368B2 (ja) 2010-03-11 2018-10-30 メチルナルトレキソンの経口製剤および親油性塩

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2015178184A Pending JP2016029054A (ja) 2010-03-11 2015-09-10 メチルナルトレキソンの経口製剤および親油性塩
JP2017152275A Active JP6429955B2 (ja) 2010-03-11 2017-08-07 メチルナルトレキソンの経口製剤および親油性塩
JP2018203748A Active JP6647368B2 (ja) 2010-03-11 2018-10-30 メチルナルトレキソンの経口製剤および親油性塩

Country Status (32)

Country Link
US (8) US8524276B2 (enExample)
EP (2) EP3178472B1 (enExample)
JP (4) JP6143409B2 (enExample)
KR (2) KR101982482B1 (enExample)
CN (2) CN102918039B (enExample)
AR (1) AR080491A1 (enExample)
AU (1) AU2011224275B2 (enExample)
BR (1) BR112012022873B1 (enExample)
CA (1) CA2789798C (enExample)
CL (1) CL2012002192A1 (enExample)
CO (1) CO6630134A2 (enExample)
CR (1) CR20120476A (enExample)
EA (1) EA029096B1 (enExample)
EC (1) ECSP12012208A (enExample)
ES (1) ES2623926T3 (enExample)
GE (1) GEP201606550B (enExample)
GT (1) GT201200247A (enExample)
HU (1) HUE033133T2 (enExample)
IL (1) IL221452A (enExample)
MA (1) MA34146B1 (enExample)
MX (2) MX368805B (enExample)
MY (1) MY160727A (enExample)
NZ (3) NZ601595A (enExample)
PE (1) PE20130063A1 (enExample)
PH (1) PH12012501622A1 (enExample)
PL (2) PL2371357T3 (enExample)
SG (3) SG10201606618PA (enExample)
TN (1) TN2012000392A1 (enExample)
TW (2) TWI589293B (enExample)
UA (2) UA123856C2 (enExample)
WO (1) WO2011112816A1 (enExample)
ZA (1) ZA201808498B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20150037T4 (hr) 2003-04-08 2022-09-02 Progenics Pharmaceuticals, Inc. Farmaceutske formulacije koje sadrže metilnaltrekson
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
CA2682129A1 (en) 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Crystal forms and uses thereof
EP2164960A2 (en) 2007-05-25 2010-03-24 North Carolina State University Viral nanoparticle cell-targeted delivery platform
EA029096B1 (ru) 2010-03-11 2018-02-28 Вайет Ллк Твердая лекарственная форма для перорального введения, содержащая метилналтрексон
US8627816B2 (en) 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US8939943B2 (en) 2011-01-26 2015-01-27 Kaleo, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
AU2012359013A1 (en) * 2011-12-19 2014-06-26 Salix Pharmaceuticals, Ltd. Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone
WO2015191686A1 (en) * 2014-06-10 2015-12-17 Salix Pharmaceuticals, Inc. Methods of administering methylnaltrexone
US10722510B2 (en) * 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
WO2016007245A1 (en) * 2014-07-08 2016-01-14 Insys Pharma, Inc. Sublingual naloxone spray
US10617686B2 (en) * 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10441538B2 (en) * 2014-07-08 2019-10-15 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
CA3002137A1 (en) 2014-10-17 2016-04-21 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progression
US20220062183A1 (en) * 2018-12-19 2022-03-03 Friulchem S.P.A. Process for the manufacture of a tablet of rifaximin and tablet of rifaximin
CN113747882A (zh) * 2019-05-07 2021-12-03 博士医疗爱尔兰有限公司 甲基纳曲酮的液体口服剂量制剂
WO2020245214A1 (en) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
WO2021224138A1 (en) 2020-05-02 2021-11-11 Bausch Health Ireland Limited Methods of reducing mortality risk in subjects suffering from an underlying disease or condition by administration of methylnaltrexone
WO2023031955A1 (en) * 2021-08-28 2023-03-09 Redasani Vijayendrakumar Virendrakumar Ji Oral pharmaceutical compositions of methylnaltrexone and salt thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4176186A (en) 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
US4719215A (en) 1986-03-07 1988-01-12 University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4861781A (en) 1986-03-07 1989-08-29 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
CA1297218C (en) 1986-03-14 1992-03-10 Edward David Weil Thermally stable diphosphonate-type flame retardant additive for plastics
US5102887A (en) 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
US5780012A (en) 1990-06-21 1998-07-14 Huland; Edith Method for reducing lung afflictions by inhalation of cytokine solutions
AU5171293A (en) 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
US5866154A (en) 1994-10-07 1999-02-02 The Dupont Merck Pharmaceutical Company Stabilized naloxone formulations
DE19651551C2 (de) 1996-12-11 2000-02-03 Klinge Co Chem Pharm Fab Opioidantagonisthaltige galenische Formulierung
CZ297951B6 (cs) 1997-02-14 2007-05-02 Gödecke Aktiengesellschaft Zpusob stabilizace naloxonu
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US20030158220A1 (en) 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
EP0913152B1 (de) 1997-11-03 2001-12-19 Stada Arzneimittel Ag Stabilisiertes Kombinationsarzneimittel enthaltend Naloxone und ein Opiatanalgetikum
US5972954A (en) 1997-11-03 1999-10-26 Arch Development Corporation Use of methylnaltrexone and related compounds
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
GB0100115D0 (en) 2001-01-04 2001-02-14 Alchemia Pty Ltd Delivery systems
CN1525851A (zh) * 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
EP1404323B1 (en) 2001-06-05 2009-10-28 The University of Chicago Use of methylnaltrexone to treat immune suppression
EP2236161A1 (en) 2001-10-18 2010-10-06 Nektar Therapeutics Polymer conjugates of opioid antagonists
MXPA04005210A (es) * 2001-11-29 2004-08-19 Schering Corp Procedimiento para la preparacion de composiciones que tienen una cantidad incrementada de sales farmaceuticamente activas de rotameros.
ATE510534T1 (de) 2002-03-14 2011-06-15 Euro Celtique Sa Naltrexonhydrochlorid-zusammensetzungen
US20030191147A1 (en) 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
HRP20150037T4 (hr) 2003-04-08 2022-09-02 Progenics Pharmaceuticals, Inc. Farmaceutske formulacije koje sadrže metilnaltrekson
AU2004229464A1 (en) 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
JP2006522817A (ja) 2003-04-08 2006-10-05 プロジェニックス ファーマシューティカルズ,インコーポレーテッド 過敏性腸症候群を処置するための末梢オピオイドアンタゴニスト、特にメチルナルトレキソンの使用
WO2005009356A2 (en) * 2003-07-15 2005-02-03 Pr Pharmaceuticals, Inc. Method for the preparation of controlled release formulations
US8946262B2 (en) 2003-12-04 2015-02-03 Adolor Corporation Methods of preventing and treating gastrointestinal dysfunction
EP1701699B1 (en) 2003-12-19 2011-07-13 Schering Corporation Pharmaceutical compositions of an A2a receptor antagonist
WO2005065656A2 (en) * 2003-12-31 2005-07-21 Pfizer Products Inc. Stabilized pharmaceutical solid compositions of low-solubility drugs, poloxamers, and stabilizing polymers
CN1294728C (zh) 2004-08-05 2007-01-10 华为技术有限公司 边缘路由器提供服务质量保证的方法及系统
ES2392645T3 (es) 2004-09-30 2012-12-12 Becton,Dickinson And Company Método para reducir o eliminar residuos en una recipiente médico de vidrio y recipiente hecho de acuerdo con el mismo
US20060177380A1 (en) * 2004-11-24 2006-08-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
AR057035A1 (es) * 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
WO2008021394A2 (en) * 2006-08-15 2008-02-21 Theraquest Biosciences, Llc Pharmaceutical formulations of cannabinoids and method of use
CA2660100C (en) * 2006-08-16 2014-10-21 Alcon Inc. Temporal photo-bleaching of colored lens care solutions and use thereof
CA2665726C (en) * 2006-10-11 2016-04-19 Alpharma, Inc. Pharmaceutical compositions
TW200843802A (en) 2007-02-09 2008-11-16 Drugtech Corp Compositions for improving gastrointestinal nutrient and drug absorption
CA2682129A1 (en) * 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Crystal forms and uses thereof
PT2139890E (pt) * 2007-03-29 2014-09-03 Wyeth Llc Antagonistas do receptor opióide periférico e respectivas utilizações
JP5178064B2 (ja) * 2007-06-27 2013-04-10 富士フイルム株式会社 金属表面粗化層を有する金属層積層体及びその製造方法
KR20110004425A (ko) * 2008-05-07 2011-01-13 넥타르 테라퓨틱스 말초적 작용 오피오이드 길항제의 경구 투여
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
JP5525247B2 (ja) * 2009-08-04 2014-06-18 株式会社神戸製鋼所 高強度で曲げ加工性に優れた銅合金
EA029096B1 (ru) 2010-03-11 2018-02-28 Вайет Ллк Твердая лекарственная форма для перорального введения, содержащая метилналтрексон
TW201235609A (en) * 2010-07-13 2012-09-01 Koninkl Philips Electronics Nv Low cost mounting of LEDs in TL-retrofit tubes

Similar Documents

Publication Publication Date Title
JP6647368B2 (ja) メチルナルトレキソンの経口製剤および親油性塩
JP7374885B2 (ja) 子宮内膜症、子宮筋腫、多嚢胞性卵巣症候群又は腺筋症を治療するための医薬製剤
CZ413497A3 (cs) Formulace s řízeným uvolňováním u špatně rozpustného léčiva
JP2008524332A (ja) 睡眠傷害のための医薬組成物
CA2601955A1 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
JP2007509055A (ja) [2−(8,9−ジオキソ−2,6−ジアザビシクロ[5.2.0]ノナ−1(7)−エン−2−イル)アルキル]ホスホン酸および誘導体の経口投与
JP2006527256A5 (enExample)
RU2017143849A (ru) Твёрдый состав для перорального применения, содержащий иринотекан, и способ его получения
WO2015010449A1 (zh) 使用维生素b组合物促进胃肠系统动力的方法
BR112014009506B1 (pt) preparação estabilizada de liberação sustentada contendo eperisona
US20170319519A1 (en) Combination for the treatment of conditions involving muscular pain
WO2014125124A1 (en) Solid pharmaceutical dosage form of dolutegravir
AU2005204014B2 (en) Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent
JP2015501849A5 (enExample)
WO2013006146A1 (en) Effervescent formulations comprising dexketoprofen
WO1999065475A2 (en) Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
WO2013052019A1 (en) Production method for effervescent formulations comprising diclofenac
WO2013180675A1 (en) Tablet formulation comprising dapoxetine
ES2897576T3 (es) Composiciones antimicrobianas con agentes efervescentes
JP4598674B2 (ja) 統合失調症治療剤
KR20250156840A (ko) 경구 생체이용률을 개선하기 위한 약학적 조성물
WO2021236891A1 (en) Gut-targeted phosphodiesterase inhibitors
CN111821269A (zh) 一种地氯雷他定口崩片的制备方法
WO2014203140A1 (en) Solid oral pharmaceutical compositions comprising fixed dose combination of acetaminophen, dicyclomine and dextropropoxyphene or salts thereof
TR201400835A2 (tr) Üçüncü kuşak sefalosporin içeren formülasyonlar.